Current Price Performance and Market Context
The stock closed at ₹107.65 on 13 Aug 2026, down 4.73% from the previous close of ₹113.00. Intraday, it fluctuated between ₹106.50 and ₹114.00, indicating some volatility. Over the past 52 weeks, Themis Medicare has traded within a range of ₹65.00 to ₹147.99, underscoring significant price swings typical of micro-cap stocks in the pharmaceutical sector.
Comparatively, the stock’s returns have diverged from the broader Sensex benchmark. Year-to-date, Themis Medicare has delivered a positive return of 6.95%, outperforming the Sensex’s negative 8.51%. However, over longer horizons, the stock has underperformed; a three-year return of -34.84% contrasts sharply with the Sensex’s 19.36% gain, reflecting sector-specific challenges and company-specific factors.
Technical Trend Evolution: From Bullish to Mildly Bullish
The recent technical parameter adjustment signals a shift from a clear bullish trend to a more tempered mildly bullish outlook. This change is informed by a comprehensive analysis of multiple technical indicators across different timeframes.
On the weekly chart, the Moving Average Convergence Divergence (MACD) remains bullish, suggesting that momentum is still positive in the medium term. The monthly MACD, however, has softened to mildly bullish, indicating a potential slowdown in upward momentum over the longer term. This divergence between weekly and monthly MACD readings highlights a transitional phase for the stock’s price action.
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This suggests that the stock is neither overbought nor oversold, leaving room for directional movement based on upcoming market catalysts.
Bollinger Bands and Moving Averages: Mixed Signals
Bollinger Bands provide further insight into volatility and price positioning. Weekly Bollinger Bands indicate a mildly bullish stance, with the price trading near the upper band, signalling some upward pressure. Conversely, the monthly Bollinger Bands have turned mildly bearish, reflecting increased volatility and a potential for price correction in the longer term.
Daily moving averages reinforce a mildly bullish trend, with short-term averages positioned above longer-term averages, albeit with a narrowing gap. This suggests that while the immediate trend is positive, momentum may be losing strength, warranting close monitoring for any reversal signs.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Additional Technical Indicators: KST, Dow Theory, and OBV
The Know Sure Thing (KST) indicator, which measures momentum across multiple timeframes, remains bullish on the weekly chart and mildly bullish on the monthly chart. This supports the notion that momentum is still intact but may be moderating.
Dow Theory analysis shows no definitive trend on either weekly or monthly charts, indicating a lack of clear directional conviction from this classical perspective. This absence of trend confirmation suggests that investors should exercise caution and await stronger signals before committing to significant positions.
On-Balance Volume (OBV) readings provide a mixed view: no trend is evident on the weekly timeframe, but the monthly OBV is bullish. This divergence implies that while short-term volume flows are inconclusive, longer-term accumulation may be occurring, potentially underpinning future price support.
Mojo Score and Grade Upgrade
Themis Medicare’s MarketsMOJO score currently stands at 53.0, reflecting a Hold rating. This is an improvement from the previous Sell grade, which was revised on 30 Jun 2026. The upgrade to Hold suggests that while the stock is not yet a strong buy, it has shown enough improvement in fundamentals and technicals to warrant cautious optimism.
As a micro-cap stock in the Pharmaceuticals & Biotechnology sector, Themis Medicare faces inherent volatility and sector-specific risks, including regulatory challenges and competitive pressures. Investors should weigh these factors alongside the technical signals before making investment decisions.
Price Momentum and Relative Strength Analysis
Examining recent price momentum, Themis Medicare has underperformed the Sensex over short-term periods. The stock declined 6.88% over the past week and 7.99% over the last month, compared to the Sensex’s modest gains of 0.51% monthly and a 0.78% weekly decline. This relative weakness may reflect profit-taking or sector rotation pressures.
However, the stock’s year-to-date return of 6.95% outpaces the Sensex’s negative 8.51%, indicating resilience amid broader market headwinds. Over one year, the stock has marginally gained 1.27%, while the Sensex fell 2.83%, further highlighting relative strength in a challenging environment.
Longer-term returns remain subdued, with a three-year loss of 34.84% contrasting with the Sensex’s 19.36% gain, and a five-year return of 4.35% versus the Sensex’s 42.16%. This underscores the importance of a cautious approach given the stock’s historical volatility and sector dynamics.
Holding Themis Medicare Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaway and Outlook
Themis Medicare’s technical indicators collectively suggest a cautious but mildly optimistic outlook. The shift from bullish to mildly bullish momentum, supported by weekly MACD and KST readings, indicates that the stock retains some upward potential. However, the lack of strong RSI signals and mixed Bollinger Band trends counsel prudence.
Investors should monitor key support levels near ₹106 and resistance around ₹114, as intraday volatility remains elevated. The absence of a clear Dow Theory trend and neutral weekly OBV further emphasise the need for careful position sizing and risk management.
Given the micro-cap status and sector-specific risks, Themis Medicare is best suited for investors with a higher risk tolerance who can withstand short-term fluctuations while seeking potential medium-term gains. The recent upgrade to a Hold rating by MarketsMOJO reflects this balanced view, acknowledging improved technical momentum without signalling a definitive buy opportunity.
In summary, Themis Medicare Ltd presents a complex technical picture with mixed signals across timeframes. While momentum indicators show some improvement, the stock’s relative underperformance in the short term and historical volatility warrant a measured approach. Investors should continue to analyse evolving technical parameters alongside fundamental developments to make informed decisions.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
